Genomic Subtyping in Bladder Cancer.

Jalanko, Tuomas; de Jong, Joep J; Gibb, Ewan A; Seiler, Roland; Black, Peter C (2020). Genomic Subtyping in Bladder Cancer. Current urology reports, 21(2), p. 9. Springer 10.1007/s11934-020-0960-y

Text Se_Genomic Subtyping in Bladder Cancer_0620.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (554kB) | Request a copy

PURPOSE OF REVIEW

Molecular characterization of cancer allows us to understand oncogenesis and clinical prognosis as well as facilitates development of biomarkers and treatment. Our aim was to review the current literature on genomic characterization of bladder cancer, and how far we are in implementing genomics into clinical practice.

RECENT FINDINGS

Bladder cancers are molecularly diverse tumors with a high mutational rate. On molecular level, bladder cancer can be categorized into at least six subtypes called luminal-papillary, luminal-unstable, luminal non-specified, basal-squamous, neuroendocrine-like, and stroma-rich. These subtypes have characteristic genomic and transcriptomic profiles and appear to have different prognoses. Several molecular subtypes have been identified in bladder cancer. Prospective trials are underway to validate the applicability of genomic subtypes for clinical decision making. Further integrative analyses of genomic alterations, gene expression, epigenetics, and proteomics need to be performed before genomic subtyping can be attained in clinical practice.

Interest & Impact

Downloads

1 since deposited on 09 Jun 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item